These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38300409)

  • 1. Use of Cas9 Targeting and Red Recombination for Designer Phage Engineering.
    Choi SY; Romero-Calle DX; Cho HG; Bae HW; Cho YH
    J Microbiol; 2024 Jan; 62(1):1-10. PubMed ID: 38300409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient Genome Engineering of a Virulent Klebsiella Bacteriophage Using CRISPR-Cas9.
    Shen J; Zhou J; Chen GQ; Xiu ZL
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29899105
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeted Genome Editing of Virulent Pseudomonas Phages Using CRISPR-Cas3.
    Schroven K; Voet M; Lavigne R; Hendrix H
    Methods Mol Biol; 2024; 2793():113-128. PubMed ID: 38526727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacteriophage genome engineering with CRISPR-Cas13a.
    Guan J; Oromí-Bosch A; Mendoza SD; Karambelkar S; Berry JD; Bondy-Denomy J
    Nat Microbiol; 2022 Dec; 7(12):1956-1966. PubMed ID: 36316452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPY-BRED and CRISPY-BRIP: efficient bacteriophage engineering.
    Wetzel KS; Guerrero-Bustamante CA; Dedrick RM; Ko CC; Freeman KG; Aull HG; Divens AM; Rock JM; Zack KM; Hatfull GF
    Sci Rep; 2021 Mar; 11(1):6796. PubMed ID: 33762639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering Bacteriophages as Versatile Biologics.
    Kilcher S; Loessner MJ
    Trends Microbiol; 2019 Apr; 27(4):355-367. PubMed ID: 30322741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic RNA Polymerase III Promoters Facilitate High-Efficiency CRISPR-Cas9-Mediated Genome Editing in Yarrowia lipolytica.
    Schwartz CM; Hussain MS; Blenner M; Wheeldon I
    ACS Synth Biol; 2016 Apr; 5(4):356-9. PubMed ID: 26714206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome Engineering of Virulent Lactococcal Phages Using CRISPR-Cas9.
    Lemay ML; Tremblay DM; Moineau S
    ACS Synth Biol; 2017 Jul; 6(7):1351-1358. PubMed ID: 28324650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition mechanisms of CRISPR-Cas9 by AcrIIA17 and AcrIIA18.
    Wang X; Li X; Ma Y; He J; Liu X; Yu G; Yin H; Zhang H
    Nucleic Acids Res; 2022 Jan; 50(1):512-521. PubMed ID: 34893860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterial Genome Editing with CRISPR-Cas9: Deletion, Integration, Single Nucleotide Modification, and Desirable "Clean" Mutant Selection in Clostridium beijerinckii as an Example.
    Wang Y; Zhang ZT; Seo SO; Lynn P; Lu T; Jin YS; Blaschek HP
    ACS Synth Biol; 2016 Jul; 5(7):721-32. PubMed ID: 27115041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of temperate phages drives loss of type I CRISPR-Cas systems.
    Rollie C; Chevallereau A; Watson BNJ; Chyou TY; Fradet O; McLeod I; Fineran PC; Brown CM; Gandon S; Westra ER
    Nature; 2020 Feb; 578(7793):149-153. PubMed ID: 31969710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing the activity of abundant, diverse and active CRISPR-Cas systems in lactobacilli.
    Crawley AB; Henriksen ED; Stout E; Brandt K; Barrangou R
    Sci Rep; 2018 Aug; 8(1):11544. PubMed ID: 30068963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-locus scarless genome editing system in Escherichia coli.
    Liu H; Hou G; Wang P; Guo G; Wang Y; Yang N; Rehman MNU; Li C; Li Q; Zheng J; Zeng J; Li S
    Biotechnol Lett; 2020 Aug; 42(8):1457-1465. PubMed ID: 32130564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-Cas9 Based Bacteriophage Genome Editing.
    Zhang X; Zhang C; Liang C; Li B; Meng F; Ai Y
    Microbiol Spectr; 2022 Aug; 10(4):e0082022. PubMed ID: 35880867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Portable CRISPR-Cas9
    Goh YJ; Barrangou R
    Appl Environ Microbiol; 2021 Feb; 87(6):. PubMed ID: 33397707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes and characterization of chromosomal self-targeting by native CRISPR-Cas systems in Streptococcus thermophilus.
    Cañez C; Selle K; Goh YJ; Barrangou R
    FEMS Microbiol Lett; 2019 May; 366(9):. PubMed ID: 31077282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eliminating mcr-1-harbouring plasmids in clinical isolates using the CRISPR/Cas9 system.
    Wang P; He D; Li B; Guo Y; Wang W; Luo X; Zhao X; Wang X
    J Antimicrob Chemother; 2019 Sep; 74(9):2559-2565. PubMed ID: 31203365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome Editing with CRISPR-Cas9: Can It Get Any Better?
    Haeussler M; Concordet JP
    J Genet Genomics; 2016 May; 43(5):239-50. PubMed ID: 27210042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The endless battle between phages and CRISPR-Cas systems in
    Philippe C; Moineau S
    Biochem Cell Biol; 2021 Aug; 99(4):397-402. PubMed ID: 33534660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal 2'-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity.
    Basila M; Kelley ML; Smith AVB
    PLoS One; 2017; 12(11):e0188593. PubMed ID: 29176845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.